Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 4/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401219 | 0.88 | ALDH1A1 (0.54) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL4178755 | 0.88 | ITGB3 (0.53) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL24795018 | 0.88 | ITGB3 (0.53) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL254638 | 0.88 | ITGB3 (0.53) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL31174184 | 0.86 | CTSL (0.49) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL27506310 | 0.85 | CTSL (0.51) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL7153638 | 0.84 | POLB (0.53) | SYKTACR1 | |
| SCHEMBL14423615 | 0.84 | POLB (0.53) | SYKTACR1 | |
| SCHEMBL5358594 | 0.84 | POLB (0.53) | SYKTACR1 | |
| SCHEMBL13995540 | 0.84 | CTSL (0.63) | CTSLCTSBCTSSCTSKITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973084-B2 | High permeability through plasma membrane, nuclear membrane and blood-brain barrier; for delivering doxorubicin and paclitaxel to target cells; gene therapy | POSTECH ACADEMY-INDUSTRIAL FOUNDATION (KR) | 2011-07-05 | — | — | US | disclosed |
| US-20080039421-A1 | Molecular Transporters Based On Alditol Or Inositol And Processes For The Preparation Thereof | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039421-A1 | Molecular Transporters Based On Alditol Or Inositol And Processes For The Preparation Thereof | ALDOA, SLC29A1, SLC29A2 | CTSL 4347/4885CTSB 4205/4885CTSS 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.